Targeting cancer with
Power+Precision tm
Welcome to Viventia Bio Inc.
Broad, Clinical-Stage Oncology Pipeline
Viventia is advancing a broad pipeline of Targeted Protein Therapeutics (TPTs), which are fully biologic fusion constructs containing antibody fragments, “Precision,” combined using a proprietary linker with protein toxin payloads “Power.”
Advanced Product Candidates
Viventia’s most advanced product candidates include ViciniumTM for the treatment of high-grade non-muscle invasive bladder cancer and ProxiniumTM for the treatment of late-stage squamous cell carcinoma of the head and neck.
Robust Platform
Viventia has additional early stage products in development that use its TPT technology platform which we expect to begin evaluating in clinical trials in 2016.
Intro to Viventia Bio Inc.
Viventia is using fusion protein technology to develop a pipeline of fully biologic molecules combining both the precision targeting of antibody fragments and the tumor cell killing power of protein cytotoxins. Viventia refers to these fully biologic entities as targeted protein therapeutics (TPTs) and is developing them for diseases in oncology.
Copyright 2016 © Viventia Bio Inc. All rights reserved